Seminars & Events
Thursday, September 11, 2014: Dr. Bevil Conway (Wellesley College) will speak on his research in visual neuroscience and color at 4:30 pm in Goodpaster Hall 195.
Monday, October 27, 2014: Dr. Todd Gould (University of Maryland Baltimore) will speak on "Genes to behaviors to treatments in bipolar disorder" at 4:45 pm in Goodpaster Hall 195.Friday, December 5, 2014: Dr. Brian Mathur (University of Maryland Baltimore) will speak on "Braking bad: Aberrant inhibitory neurotransmission in addiction" at 3:00 pm in Goodpaster Hall 195.
Singley, Rachel (2012). Ototoxicity and otoprotection in the goldfish (Carassius auratus) lateral line system. (Mentor: J. Ramcharitar)
Many life-saving drugs result in irreversible ototoxicity, the destruction of mechanosensory hair cells, which implies ongoing deficits in balance (e.g. vertigo) and hearing loss. As the cellular mechanisms of various ototoxic compounds are realized, different molecules emerge as possible otoprotectants that can prevent hair cell death without preventing a drug’s therapeutic effects. Hair cells are found in the semicircular canals and cochlea of the mammalian inner ear, similar structures in other vertebrate ears, and the neuromasts of the fish lateral line system. The fish lateral line system is a model system for ototoxicity and otoprotection studies due to similarities between its hair cells and those in mammals. This study developed dose-response curves for the effects of cisplatin and gentamicin on neuromast death in adult goldfish, with the hypothesis that both drugs would show a dose-dependent neuromast decrease. Both ototoxins demonstrated the expected relationship, although cisplatin’s dose-response curve better fit the data. This study also examined the dose-response relationship between epicatechin treatment before 50 µM cisplatin exposure and neuromast survival, with the hypothesis that epicatechin would show a dose-dependent neuromast increase. The epicatechin dose-response curve supported this hypothesis. These findings contribute to the current knowledge by providing additional information about dose-related effects of these drugs, with the hope that similar studies will eventually lead to the development of FDA-approved otoprotective drugs.